Kannan Natarajan, PhD, Pfizer, Brooklyn, NY, shares his thoughts on the impact of the COVID-19 pandemic in oncology. Restricted access to hospitals and clinical sites significantly disrupted the cancer care system and severely impacted clinical trials, with many having to be suspended. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.